RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Sihuan Pharma has started a China clinical trial of favipiravir, an RNA polymerase inhibitor, to treat COVID-19. The oral drug was co-developed by Sihuan and the Institute of Microbiology Epidemiology of the Academy of Military Medical Sciences. In 2014, Sihuan’s tests of favipiravir showed it was an effective treatment for Ebola. China’s Human Genetic Resources Management Office reviewed and approved the COVID-19 trial in one day. If favipiravir proves effective against the COVID-19 virus, Sihuan promised to distribute it for free.
Source: China Biotoday
